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lower HDL-C levels (56.5±16 mg/dl versus 63.7±18;
p=0.005), and more cases above the high risk cut-
points for cholesterol/HDL-C (14% versus 4.1%;
p=0.01) and for AIP (15% versus 6.1%; p=0.03). Also,
uric acid levels are higher in SLE women (4.8±1.5
mg/dl) than in RA (4.1±1.1 mg/dl), p=0.001. On the
other hand, insulin resistance is significantly hig-
her in women with RA as compared with SLE (me-
dian HOMA-IR 3.5 [6.4]) versus 0.72 [2.5]; p<0.0001)
and the difference remained significant after ad-
justment for BMI and corticosteroids. 
Conclusions: Cardiovascular risk profile is distinct
in SLE and RA women and the contribution of tra-
ditional CV risk factors to atherogenesis may be dif-
ferent in these two diseases. Prospective studies are
necessary to understand how the control of modi-
fiable risks can improve CV outcome in different in-
flammatory settings. 
Introduction  
The importance of premature atherosclerosis in
Systemic Lupus Erythematosus (SLE) and Rheu-
matoid Arthritis (RA) is well established in popula-
tion and cohort-based studies. Atherosclerotic
complications account for the majority of late
deaths in SLE1 and represent the primary cause of
death in half of the RA patients2,3. The incidence ra-
tes of myocardial infarction (MI) and angina in pre-
menopausal lupus women is 50 times higher than
in matched controls4 and among RA women the
observed incidence of MI is also greater than expec-
ted5. Furthermore, studies dealing with subclinical
atherosclerosis showed the magnitude of this pro-
blem to be superior in SLE and RA as compared to
the general population6,7. 
However, some differences in CV risk appear to
exist between the two diseases. While the reported
risk of ischemic heart disease is 5-8 folds higher in
SLE patients8,9, this increased risk is only 2-3 folds
higher in RA patients10,11. In both diseases the rela-
Abstract 
Objective: Premature atherosclerosis is well-docu-
mented both in Systemic Lupus Erythematosus
(SLE) and in Rheumatoid Arthritis (RA) patients,
but cardiovascular (CV) risk is particularly high in
lupus women. Although conventional CV risk fac-
tors do not fully explain the excessive risk in in-
flammatory diseases, they remain major contribu-
tors to atherosclerosis. The aim of the present study
was to investigate whether CV risk factors are dif-
ferentially associated with SLE and RA. 
Methods: One hundred women with SLE, 98 with
RA and 102 controls matched on age and without
overt CV or renal disease were assessed for the pre-
sence of Framingham (hypertension, hypercholes-
terolemia, low HDL, diabetes, smoking) and other
CV risks (atherogenic index of plasma (AIP), insu-
lin resistance, obesity, central obesity, metabolic
syndrome, uric acid, sedentarism, hypothyroidism
and family history of premature CV disease).
Results: Modifiable CV risk factors are highly pre-
valent and occur more frequently in SLE and RA
than in age-matched controls. Some differences in
Framingham risk factors were found between SLE
and RA, with hypertension being more common in
young lupus women, hypercholesterolemia more
frequent in RA and low HDL-C more frequent in
SLE. However, the estimated 10-year Framingham
CHD risk or the Reynolds Risk Score was compara-
ble in both diseases. Although hypercholesterole-
mia was more frequent in RA, lupus women display
a more atherogenic lipid profile, with significantly
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tive risk is more pronounced in youngest fema-
les4,6,7.
Accelerated atherosclerosis in SLE and RA can-
not be fully explained by traditional CV risk fac-
tors8,11. Nevertheless, conventional risk factors ex-
plain a substantial part of premature atherosclero-
sis12,13 and, as many of them are modifiable, recom-
mendations for their screening and control in
inflammatory rheumatic disease have been deve-
loped14,15.
The prevalence of hypertension, dyslipoprotei-
nemia and sedentary lifestyle seems to be increa-
sed both in SLE and RA, though different studies
provide a wide range of results 4,8,16,17,18. However,
there is limited information about the relative pre-
valence of CV risk factors in SLE and RA and to
what extent this could account for the observed
difference in CV events.
We examined the presence of classic Fra-
mingham and other conventional CV risk factors
in SLE and RA women of similar age and without
overt cardiovascular disease or renal function im-
pairment to specifically address whether major dif-
ferences exist between these two chronic inflam-
matory diseases of different pathogenesis. The Fra-
mingham 10-year risk of major heart events was es-
timated and, given the inflammatory setting of the
study population, Reynolds Risk Score was also
calculated. In addition, we assessed the distri-
bution of CV risk factors in a control group to dis-
tinguish which factors are overrepresented in SLE
and RA.
Material and methods
Patients
Adult women, fulfilling the American College of
Rheumatology criteria for SLE or RA and attending
the rheumatology clinic at Hospital Garcia de Orta
in Almada, Portugal, on a regular basis, were recrui-
ted between January and December 2009. The con-
trol group consisted of women without chronic in-
flammatory disorders (patients with tendinitis or
with low back pain) attending the same clinic. Ex-
clusion criteria were: pregnancy, breastfeeding,
prevalent myocardial infarction, angina pectoris,
coronary revascularization, ischemic stroke and
impaired renal function. In order to guarantee re-
presentativeness of different age groups, partici-
pants were enrolled in a consecutive way and allo-
cated according to age frequency to obtain a final
sample of 30% aged 18-39 years, 45% aged 40-59
years, and 25% aged ≥60 years. The study was ap-
proved by the local Ethics Committee and partici-
pants provided written informed consent. 
Assessments
Participants underwent a structured interview,
physical examination and laboratory evaluation.
Age, ethnicity, menopausal status, number of years
of education, smoking, physical activity, disease
duration from the physician’s diagnosis, current
medication, co-morbidities and family history of
CV events was assessed. Information on cumula-
tive corticosteroid dose was obtained from review
of patients’ medical records. Current disease acti-
vity was evaluated using the SLE Disease Activity
Index 2000 (SLEDAI2K)19 and in RA patients 28
joints were examined for tenderness and swelling,
and the disease activity score (DAS28) was calcu-
lated using erythrocyte sedimentation rate20. Da-
mage was scored according to the Systemic Lupus
International Collaborating Clinics/ACR Damage
Index (SDI)21 and RA functional status was evalua-
ted using the Stanford Health Assessment Questi-
onnaire Disability Index (HAQ)22.
Standing height, weight, waist circumference
and blood pressure were measured and body mass
index (BMI) (Kg/m2) calculated. A fasting blood
sample was obtained for measurement of plasma
glucose, insulin, total cholesterol, high density li-
poprotein (HDL-C), low density lipoprotein (LDL-
C), triglycerides, uric acid and thyroid stimulating
hormone (TSH). Insulin resistance was estimated
by homeostasis model assessment (HOMA-IR) us-
ing the formula HOMA-IR= [fasting insulin
(µU/ml) × fasting glucose (mmol/l)]/22.5. The ra-
tio total cholesterol/HDL-C and the atherogenic
index of plasma (AIP), defined as the logarithm of
the ratio plasma triglycerides (mmol/l)/HDL
(mmol/l)23, were calculated. Cardiovascular risk
factors were defined as follows: hypertension as a
recorded blood pressure ≥140/90 mm/Hg or use of
antihypertensive medication; dyslipidemia as a to-
tal cholesterol ≥200 mg/dl or LDL cholesterol ≥130
mg/dl or HDL cholesterol < 50 mg/dl or triglyceri-
des ≥150 mg/dl or use of lipid-lowering agents; dia-
betes as a fasting glucose level ≥126 mg/dl, a self-
reported physician diagnosis or pharmacologic
treatment; insulin resistance was defined by an
HOMA-IR in the top quartile of a non-diabetic po-
pulation (>2.114)24, impaired fasting glucose
(≥110mg/dl) or diabetes; obesity was considered if
 
ÓRGÃO OF IC IAL DA SOC IEDADE PORTUGUESA DE REUMATOLOGIA - ACTA REUMATOL PORT. 2010;35:325-332
327
MARIA JOSÉ SANTOS E COL.
BMI ≥30 Kg/m2; central obesity if the waist cir-
cumference was above the IDF population recom-
mended cut-points25; current smoker if the parti-
cipant smoked ≥1 cigarettes per day during the last
month; sedentary lifestyle if the amount of self-re-
ported weekly exercise during the last 12 months
was <3 times or <30 min per session; family history
of premature CV events was defined as myocardial
infarction or ischemic stroke occurred in a first-de-
gree relative before the age of 55 years in males or
before the age of 65 years in females. Metabolic
syndrome was diagnosed according to the joint
definition of the International Diabetes Federa-
tion, National Heart Lung and Blood Institute,
American Heart Association, World Heart Federa-
tion, International Atherosclerosis Society and In-
ternational Association for the Study of Obesity
and using waist circumference ≥80 cm as the
threshold for abdominal obesity26.
For estimation of absolute 10-year risk for major
coronary heart disease (CHD) events we utilized
the predictive model based on the Framingham risk
score algorithm developed by Wilson et al27. This
algorithm assesses the probability of having a MI or
cardiac death during the next 10 years on the basis
of the risk factor profiles and was developed for pe-
ople 30 to 74 years old. The model includes gender,
age, diabetes, smoking status, blood pressure, total
cholesterol and HDL cholesterol as risk predictors.
The Reynolds Risk Score predicts global cardiovas-
cular risk (MI, coronary revascularization, ische-
mic stroke and cardiovascular mortality) and in-
corporates C-reactive protein levels (CRP) and fa-
mily history of premature CV disease28. The 10-year
risks were categorized into low (predicted risk
<10%), intermediate (predicted risk 10-20%) and
high (predicted risk >20%)29.
Statistical analysis
Calculations were performed using SPSS 17.0
software for Windows and a 2-tailed p value <0.05
was selected as significant. Continuous variables
are presented as means ± standard deviations or
medians and inter-quartile ranges depending on
whether the data were normally distributed or not.
Categorical variables are reported as proportions.
Comparisons between SLE and RA groups were
made using chi-square or Fisher’s exact test and
Student t-tests for independent samples. The
Mann Whitney U tests were used to compare vari-
ables that were highly skewed. Intergroup diffe-
rences in CV risk factors were also calculated
between each age stratum: 18-39 years, 40-59 years
and ≥ 60 years. We also compared the disease group
(SLE plus RA) with the control group using the
same tests. 
To evaluate the independence of the associati-
on between the diagnosis and CV risk factors we
used binary logistic regression analysis. HOMA-IR,
AIP and cholesterol/HDL-C ratio were dichotomi-
zed below and above high risk cutoffs. Multiple li-
near regression analysis was used to assess the in-
dependent relationship between diagnosis and li-
pid levels. 
Results
Demographic and disease characteristics
We studied 300 women, 100 with SLE, 98 with RA
and 102 controls, with a similar mean age, but a hig-
her proportion of non-Caucasians among patients
(14% of SLE and 11.2% of RA versus 2.9% of con-
trols). The educational level and the proportion of
postmenopausal women were comparable in the
three groups (Table I). The median duration since
SLE diagnosis was 6.6 (range 0.5 - 34) years. Arthri-
tis had occurred in 78%, renal disease in 28%, sero-
sitis in 26%, hemolytic anemia in 15% and lupus
psychosis in 5% of SLE cases. All SLE patients were
ANA positive, 80% were anti-dsDNA positive and
37% tested positive either for anti-cardiolipin, lupus
anticoagulant or both. At the time of the evaluation
83% had low disease activity (SLEDAI2K <6) and
42% presented some irreversible damage (SDI≥1).
Sixty patients were taking steroids in a median dai-
ly dose of 7.5 mg (range 1.25 to 60 mg) of predniso-
lone equivalent. The majority (73%) was currently
on antimalarials and 24% on immunossupressants. 
The median duration of RA was 7.6 (range 0.5 to
30) years, 59.2% had erosive disease and 88.8% tes-
ted positive either for rheumatoid factor (RF), anti-
CCP antibodies or both. The mean disease activity
score (DAS28) was 4.24 and the mean HAQ 1.15.
Fifty two (53.1%) patients were taking corticoste-
roids in a median dose of 5 mg/day (range 2.5 to
15 mg), 89 (91%) were currently receiving synthe-
tic DMARDs, the most commonly used was metho-
trexate in 81 cases, and 39 (40%) were on biologics. 
Framingham CHD risk factors and predicted 
10-year risk  
The presence of Framingham CHD risk factors, i.e.
hypertension, hypercholesterolemia, low-HDL,
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Table I. Demographic and clinical characteristics of study subjects
SLE RA Controls 
Characteristic (n = 100) (n = 98) (n = 102)
Age, years 46.6 ± 13.4 49.2 ± 13.7 47.7±13.4
Caucasian, (%) 86 (86) 87 (88.8) 99 (97.1 )
Education, years 8.5 [8] 9 [8] 9 [8]
Postmenopausal, (%) 50 (50) 54 (55.7) 55 (53.9)
Disease duration, years 6.6 [6.8] 7.6 [9.1] –
SLEDAI2K 2 [4] – –
DAS 28 4.24 ± 1.28 – –
SDI 0 [1] – –
HAQ 1.15 ± 0.7 – –
NSAIDs, (%) 28 (28) 62 (63.3) 23 (22.5)
Steroids, (%) 60 (60) 52 (53.1) –
Current steroid dose, mg 7.5 [12] 5 [0] –
Cumulative steroid dose, g 7.7 [18] 6.4 [15] –
Methotrexate therapy, (%) 9 (9) 81 (82.7) –
Antimalarial therapy, (%) 73 (73) 19 (19.4) –
TNF blocker therapy, (%) – 39 (40) –
Immunosuppressive therapy, (%) 24 (24) – –
Continuous variables are presented as means ± SD or median [IQR] according to the distribution and categorical variables as absolute values and proportions (%)
diabetes and smoking, occurred very often in the
studied population: 83% of SLE, 79.6% of RA and
81% of control women presented at least on risk fac-
tor. The mean number of Framingham CHD risk
factors was similar in SLE, RA and controls (1.56±0.9;
1.57±0.9 and 1.51±1.1, respectively).  Patients were
significantly more likely to have hypertension
(OR=1.97, 95%CI 1.19-3.24, p=0.008); otherwise the
distribution of CHD risk factors was similar in the 3
groups.  The mean Framingham 10-year risk of ma-
jor CHD events was 4.4% for SLE, 4.9% for RA and
4.5% for controls. Similarly, Reynolds Risk Score did
not show significant differences among the groups:
SLE 2.5%; RA 2.8%; controls 2.2%. 
Hypertension was significantly more prevalent
in SLE women aged 18-39 years (34.3%) than in RA
women within the same age range (11%; p=0.04).
The mean values of systolic and diastolic blood
pressure in SLE and RA were 128±21/76±11 mmHg
and 127±21/75±12 mmHg, respectively, but more
women in the SLE group received anti-hypertensi-
ve treatment (45% vs 32.6%; p=0.05). Differences
between SLE and RA groups could be detected in
the prevalence of hypercholesterolemia and low-
HDL, but again lupus patients were found to recei-
ve lipid-lowering treatment more frequently than
RA (39% vs 20.4%; p=0.004).
Lipid levels and atherogenic index of plasma
Fasting lipid levels were measured in all participants
and mean values are shown in Table III. To determi-
ne the independent association of SLE and RA di-
agnosis with lipid levels we used multiple regressi-
on analysis adjusted for the identified potential con-
founders (lipid lowering therapy and current corti-
costeroid dose). SLE diagnosis was significantly
associated with lower levels of total cholesterol as
well as HDL-C and LDL-C. However, when we cal-
culated the balance between risk and protective li-
pid fractions, lupus women were more likely to have
cholesterol/HDL ratio (OR=3.92, 95%CI 1.24 to
12.48, p=0.02) and AIP values (OR=2.77, 95%CI 1.03-
7.49, p=0.04) above the high risk cut-points.
Distribution of other CV risk factors 
Several CV risk factors have been described 
beyond the classic Framingham ones. We evaluated
the presence of insulin resistance, obesity, abdomi-
nal obesity, metabolic syndrome, hypothyroidism,
uric acid levels and family history of premature CV
disease. Table IV shows the presence of these risk
factors in SLE, RA and control women.
HOMA index and uric acid levels are significantly
higher in patients than in controls, as well as the
proportion of insulin resistance, central obesity,
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metabolic syndrome and hypothyroidism. More
RA than SLE women are insulin resistant (OR=3.33,
95%CI 1.75-6.36, p=<0.0001) and the association
between insulin resistance and RA diagnosis re-
mained significant after adjustment for BMI and
current corticosteroid dose (p=0.02).
We found uric acid concentration to be higher
in lupus women, even in the absence of renal im-
pairment or history of gout. The relationship
between uric acid and SLE diagnosis remained sig-
nificant irrespective of the use of anti-hypertensi-
ve medication (p=0.004). Additionally, more RA pa-
tients had a positive family history of premature
cardiovascular events.
Discussion
In the present study we found CV risk factors to be
very common in SLE and RA women and that some
Table II. Distribution of traditional Framingham CHD risk factors in women with SLE, RA and 
non-inflammatory controls
SLE RA Controls 
(n =100) (n = 98) p-value (n=102)
Hypertension, (%) 53 (53) 43 (43.9) ns 33 (32.4)*
18-39y 12 (34.3) 3 (11.1) 0.04 2 (6.5)†
40-59y 25 (58.1) 16 (36.4) ns 16 (33.3)
≥60y 16 (72.7) 24 (88.9) ns 15 (65.2)
Hypercholesterolemia, (%) 37 (37) 53 (54) 0.01 57 (55.9)
18-39y 12 (34.3) 9 (33.3) ns 13 (41.9)
40-59y 11 (25.6) 26 (60.5) 0.001 27 (56.3)
≥60y 7 (37.2) 18 (66.7) ns 17 (73.9)
Low HDL-C, (%) 39 (39) 20 (20.4) 0.005 24 (23.8)
18-39y 15 (45.5) 5 (18.5) 0.02 7 (22.3)
40-59y 15 (37.5) 9 (20.9) ns 11 (23.4)
≥60y 9 (37.4) 6 (22.2) ns 6 (26.1)
Diabetes, (%) 8 (8) 7 (7.1) ns 7 (6.9)
Current smoker, (%) 15 (15) 17 (17.3) ns 19 (18.6)
18-39y 7 (20) 6 (22) ns 9 (29)
40-59y 8 (18.6) 11 (25) ns 10 (20.8)
≥60y 0 0 ns 0
Framingham CHD risk ≥ 10%, (%) 11/88 (12.5) 16/91(17.6) ns 15/91 (16.5)
*significant difference between patients and controls p=0.008; †p=0.04
Table III. Lipid levels and atherogenic index of plasma
SLE RA Controls 
(n=100) (n=98) Adjusted p* (n=102)
Total cholesterol, mg/dl 191.6 ± 43.5 203.3 ± 33.8 0.001 206.9 ± 33.8
LDL-C, mg/dl 114.7 ± 37 122.8 ± 28 0.01 127.9 ± 29
HDL-C, mg/dl 56.5 ± 16 63.7 ± 18 0.006 62.2 ± 15
Triglycerides, mg/dl 125.3 ± 78 103.9 ± 44 ns 98 ± 41
Cholesterol/HDL-C >5, (%) 14 (14) 4 (4.1) 0.01 9 (8.8)
AIP >0.21, (%) 15 (15) 6 (6.1) 0.03 6 (5.9)
The proportion of patients receiving lipid lowering medication was: SLE-39%; RA-20.4%; controls- 24.5% (p=0.009)
AIP– atherogenic index of plasma
*adjusted for use of lipid lowering therapies, and current corticosteroid dose
 
differences could be detected between these two
inflammatory diseases and the control population.
Metabolic syndrome, as well as some features of
this syndrome, such as hypertension, insulin resis-
tance, and central obesity, are overrepresented
among SLE and RA patients. Decreased thyroid
function was also found more frequently in both
patient groups. 
We could also depict differences in the prevalen-
ce of CV risk factors between SLE and RA women.
With regard to Framingham risk factors, hyperten-
sion is more common in young lupus women and
the alterations in lipid profile are distinct in SLE
and RA patients. Despite lower total cholesterol, lu-
pus women present a more atherogenic lipid pro-
file characterized by lower HDL-C and a more
harmful balance between risk and protective lipid
fractions. Furthermore, the association of athero-
genic lipid profile with SLE diagnosis persists, ir-
respective of the use of lipid-lowering agents or
corticosteroids. Indeed, systemic inflammation
may induce alterations in lipoprotein profile and
in SLE patients it was shown that both disease acti-
vity and medication (corticosteroids and lipid-
lowering agents) contribute to the changes in lipids
that occur over time30. Active RA is also associated
with a more atherogenic lipid profile and these
changes have been documented even years befo-
re RA was diagnosed31. Furthermore, not only the
levels of atheroprotective lipids are decreased, but
also their function may be impaired in inflamma-
tory rheumatic diseases32.  Thus, identification of
a more atherogenic lipid profile in lupus women,
despite low disease activity and greater use of lipid-
lowering agents is of interest because this suggests
that the mechanisms underlying dyslipoproteine-
mia may differ in different inflammatory condi-
tions.
In the general population, increased uric acid le-
vels are an independent marker of cardiovascular
disease33 and arterial stiffness may represent the
link between hyperuricemia and atherosclerosis34.
We found higher uric acid levels in lupus women,
despite normal creatinine levels and the absence
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Table IV. Distribution of other conventional cardiovascular risk factors
SLE RA Controls 
(n =100) (n = 98) p-value (n=102)
HOMA-IR 0.72 [2.5] 3.5 [6.4] 0.0001 0.46 [0.9]*
Insulin resistant, n (%) 35 (35) 61 (62.2) 0.0001 20 (19.6)*
Obesity, n (%) 28 (28) 31 (32) ns 28 (27.5)
18-39y 8 (22.9) 5 (19.2) ns 3 (9.3)
40-59y 15 (27.3) 12 (34.9) ns 14 (29.2)
≥ ≥60y 5 (22.7) 14 (51.4) ns 11 (47.8)
Central obesity, n (%) 72 (72) 78 (79.6) ns 64 (62.3)**
18-39y 20 (57.1) 20 (66.3) ns 11 (35.5)**
40-59y 35 (81.4) 33 (75.6) ns 34 (70.8)
≥60y 17 (77.3) 25 (95.8) ns 19 (82.6)
Sedentary lifestyle, n (%) 84 (84) 87 (88.7) ns 83 (82.2)
18-39y 28 (80) 20 (74.1) ns 24 (80)
40-59y 35 (81.4) 42 (95.5) ns 42 (87.5)
≥60y 21 (95.5) 25 (92.6) ns 17 (73.9)
Metabolic Syndrome 27 (27) 25 (25.5) ns 16 (15.7)†
18-39y 5 (14.3) 2 (7.7) ns 0 (0)†
40-59y 12 (27.9) 12 (27.3) ns 7 (14.6)
≥60y 10 (45.5) 10 (37) ns 9 (39.1)
Hypothyroidism (%) 7 (7) 11 (11.2) ns 3 (2.9)†
Uric acid, mg/dl 4.8 ± 1.5 4.1 ± 1.1 0.001 3.8 ± 1.0*
Family history of premature CV 2 (2) 14 (14.3) 0.002 14 (13.7)
disease, n (%)
*significant difference between patients and controls p=0.0001; ** p=0.02; †p=0.04
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of gout.  This increase was independent of the use
of anti-hypertensive medication. We cannot rule
out a subclinical renal impairment underlying the
increased uric acid. Nevertheless, elevated uric
acid may represent an additional risk for CV disea-
se in lupus patients. 
Insulin resistance, which is fundamental to the
metabolic syndrome, was associated with sympto-
matic cardiovascular disease in the general popu-
lation35. We found HOMA-IR to be significantly in-
creased in RA as compared with SLE and this in-
crease to be independent of BMI or corticosteroids.
A previous study also demonstrated higher HOMA
index in RA than in SLE and the association of in-
sulin resistance with inflammation and coronary
atherosclerosis36. This may be an important target
to reduce CV risk in this patient population. 
Hypothyroidism is associated with a wide ran-
ge of metabolic changes, including increased BMI
and adverse lipoprotein profile. There is also a re-
lationship between hypothyroidism, vascular
dysfunction and accelerated atherosclerosis37. Al-
though hypothyroidism was more frequent in pa-
tients than in controls, its prevalence was similar
in SLE and RA women.
A comprehensive identification of cardiovascu-
lar risk profile of SLE and RA is an opportunity to
improve health management of these patients. As
most of the identified risk factors are susceptible
of intervention and modification, future research
is crucial in order to establish to what extent the
control of modifiable risk factors can improve car-
diovascular outcome of these patients.
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